{"_links": {"parentPackage": {"href": "/mdr/ct/packages/sdtmct-2016-06-24", "title": "SDTM Controlled Terminology Package 26 Effective 2016-06-24", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/sdtmct-2016-03-25/codelists/C67152", "title": "CDISC SDTM Trial Summary Parameter Long Name Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/sdtmct/codelists/C67152", "title": "Version-agnostic anchor resource for codelist C67152", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/sdtmct-2016-06-24/codelists/C67152", "title": "CDISC SDTM Trial Summary Parameter Long Name Terminology", "type": "Code List"}}, "conceptId": "C67152", "definition": "The test name for an individual characteristic of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial.", "extensible": "true", "name": "Trial Summary Parameter Test Name", "preferredTerm": "CDISC SDTM Trial Summary Parameter Long Name Terminology", "submissionValue": "TSPARM", "synonyms": ["Trial Summary Parameter Test Name"], "terms": [{"conceptId": "C98703", "definition": "Actual number of subjects enrolled; may include subjects who were not randomized.", "preferredTerm": "Actual Subject Number", "submissionValue": "Actual Number of Subjects", "synonyms": ["Actual Number of Subjects"]}, {"conceptId": "C98704", "definition": "Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study.", "preferredTerm": "Adaptive Design", "submissionValue": "Adaptive Design", "synonyms": ["Adaptive Design"]}, {"conceptId": "C49703", "definition": "The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products.", "preferredTerm": "Test Product Added to Existing Treatment", "submissionValue": "Added on to Existing Treatments", "synonyms": ["Added on to Existing Treatments"]}, {"conceptId": "C126058", "definition": "A textual description as to whether a biospecimen is retained and/or contains DNA.", "preferredTerm": "Biospecimen Retained and/or Contains DNA Indicator", "submissionValue": "Biospecimen Retention Contains DNA", "synonyms": ["Biospecimen Retention Contains DNA"]}, {"conceptId": "C127788", "definition": "A bibliographical reference related to a particular study.", "preferredTerm": "Clinical Study Citation", "submissionValue": "Citation Used in Study", "synonyms": ["Citation Used in Study"]}, {"conceptId": "C70793", "definition": "An entity that is responsible for the initiation, management, and/or financing of a clinical study.", "preferredTerm": "Clinical Study Sponsor", "submissionValue": "Clinical Study Sponsor", "synonyms": ["Clinical Study Sponsor", "Sponsor", "Study Sponsor"]}, {"conceptId": "C127789", "definition": "The state or condition of the sponsor as pertains to whether the sponsor is considered a commercial entity.", "preferredTerm": "Sponsor Commercial Status", "submissionValue": "Commercial Sponsor Status", "synonyms": ["Commercial Sponsor Status"]}, {"conceptId": "C68612", "definition": "A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial.", "preferredTerm": "Active Comparator Drug", "submissionValue": "Comparative Treatment Name", "synonyms": ["Comparative Treatment Name"]}, {"conceptId": "C98715", "definition": "The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment.", "preferredTerm": "Confirmed Response Minimum Duration", "submissionValue": "Confirmed Response Minimum Duration", "synonyms": ["Confirmed Response Minimum Duration"]}, {"conceptId": "C49647", "definition": "Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature).", "preferredTerm": "Control Type", "submissionValue": "Control Type", "synonyms": ["Control Type"]}, {"conceptId": "C124455", "definition": "The name of the country within which the final product under study is produced.", "preferredTerm": "Country of Manufacture", "submissionValue": "Country of Manufacture", "synonyms": ["Country of Manufacture"]}, {"conceptId": "C85582", "definition": "The literal identifier of the therapy or medication that is currently being given per protocol.", "preferredTerm": "Current Therapy", "submissionValue": "Current Therapy or Treatment", "synonyms": ["Current Therapy or Treatment"]}, {"conceptId": "C98717", "definition": "A date which indicates any data collected by this date will be used for analysis.", "preferredTerm": "Data Cutoff Date", "submissionValue": "Data Cutoff Date", "synonyms": ["Data Cutoff Date"]}, {"conceptId": "C98718", "definition": "Text that describes the cutoff date.", "preferredTerm": "Data Cutoff Date Description", "submissionValue": "Data Cutoff Description", "synonyms": ["Data Cutoff Description"]}, {"conceptId": "C127790", "definition": "An indication as to whether the clinical trial has an appointed data monitoring committee.", "preferredTerm": "Data Monitoring Committee Indicator", "submissionValue": "Data Monitoring Committee Indicator", "synonyms": ["Data Monitoring Committee Indicator"]}, {"conceptId": "C49650", "definition": "A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI)", "preferredTerm": "Diagnosis Group", "submissionValue": "Diagnosis Group", "synonyms": ["Diagnosis Group"]}, {"conceptId": "C117960", "definition": "A standard from which a judgment concerning a medical diagnosis can be established.", "preferredTerm": "Diagnostic Criteria", "submissionValue": "Diagnostic Criteria", "synonyms": ["Diagnostic Criteria"]}, {"conceptId": "C73558", "definition": "The unit of measure for the dosage form.", "preferredTerm": "Dosage Form Unit", "submissionValue": "Dose Units", "synonyms": ["Dose Units"]}, {"conceptId": "C25488", "definition": "The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary)", "preferredTerm": "Dose", "submissionValue": "Dose per Administration", "synonyms": ["Dose Level", "Dose per Administration"]}, {"conceptId": "C89081", "definition": "The number of doses administered per a specific interval.", "preferredTerm": "Dose Frequency", "submissionValue": "Dosing Frequency", "synonyms": ["Dosing Frequency"]}, {"conceptId": "C119561", "definition": "Indicates whether the 10-second ECGs for this study were extracted from a continuous recording.", "preferredTerm": "ECG Continuous Monitoring Indicator", "submissionValue": "ECG Continuous Monitoring", "synonyms": ["ECG Continuous Monitoring"]}, {"conceptId": "C119562", "definition": "The ECG lead which was planned to be used for ECG interval measurements for this study.", "preferredTerm": "ECG Planned Primary Lead for Study", "submissionValue": "ECG Planned Primary Lead", "synonyms": ["ECG Planned Primary Lead"]}, {"conceptId": "C119564", "definition": "The degree of automation involved in assessing the ECGs for this study.", "preferredTerm": "ECG Read Method Degree of Automation", "submissionValue": "ECG Read Method", "synonyms": ["ECG Read Method"]}, {"conceptId": "C119560", "definition": "Indicates whether assessors of ECGs for this study were blinded to subject identity, timing and treatment.", "preferredTerm": "ECG Evaluator Blinding Parameters", "submissionValue": "ECG Reading Blinded", "synonyms": ["ECG Reading Blinded"]}, {"conceptId": "C119566", "definition": "Indicates whether this study includes replicate ECGs for time points during the on-treatment portion of the study.", "preferredTerm": "ECG Replicates On-Treatment Indicator", "submissionValue": "ECG Replicates On-Treatment", "synonyms": ["ECG Replicates On-Treatment"]}, {"conceptId": "C119565", "definition": "Indicates whether this study includes replicate ECGs for time points during the baseline portion of the study.", "preferredTerm": "ECG Replicates at Baseline Indicator", "submissionValue": "ECG Replicates at Baseline", "synonyms": ["ECG Replicates at Baseline"]}, {"conceptId": "C119582", "definition": "The algorithm used to identify the end of the T wave for ECGs for this study.", "preferredTerm": "ECG T Wave Algorithm", "submissionValue": "ECG Twave Algorithm", "synonyms": ["ECG Twave Algorithm"]}, {"conceptId": "C119563", "definition": "Indicates whether all ECG interval measurements for the study were based on the same lead.", "preferredTerm": "ECG Used Same Lead Indicator", "submissionValue": "ECG Used Same Lead", "synonyms": ["ECG Used Same Lead"]}, {"conceptId": "C126059", "definition": "An alphanumeric code assigned by the European Medicines Agency (EMA) to an EMA regulatory decision for a pediatric investigation plan (PIP).", "preferredTerm": "EMA Decision Number for Pediatric Investigation Plan", "submissionValue": "EMA Decision Number for PIP", "synonyms": ["EMA Decision Number for PIP"]}, {"conceptId": "C127791", "definition": "The Email address to which copies of the XML format of the EudraCT application should be sent.", "preferredTerm": "E-mail Address for XML File Feedback", "submissionValue": "Email Address for XML File", "synonyms": ["Email Address for XML File"]}, {"conceptId": "C126060", "definition": "An indication as to whether the trial being submitted to the EudraCT is a trial that has been previously submitted to the EudraCT system.", "preferredTerm": "EudraCT Resubmission Indicator", "submissionValue": "EudraCT Resubmission Indicator", "synonyms": ["EudraCT Resubmission Indicator"]}, {"conceptId": "C126061", "definition": "A unique identifier assigned to the organization that is transmitting an adverse drug reaction report to the EudraVigilance system.", "preferredTerm": "EudraVigilance Sender Identifier", "submissionValue": "EudraVigilance Sender ID", "synonyms": ["EudraVigilance Sender ID"]}, {"conceptId": "C126090", "definition": "The name of the group or institution that is transmitting an adverse drug reaction report to the EudraVigilance system.", "preferredTerm": "EudraVigilance Sender Organization", "submissionValue": "EudraVigilance Sender Organization", "synonyms": ["EudraVigilance Sender Organization"]}, {"conceptId": "C127792", "definition": "The unique alphanumeric identifier for the study with associated expanded access record, as assigned by the clinicaltrials.gov protocol registration and results system (PRS).", "preferredTerm": "Clinicaltrials.gov NCT Number for the Expanded Access Record", "submissionValue": "Expanded Access Record NCT Number", "synonyms": ["Expanded Access Record NCT Number"]}, {"conceptId": "C127793", "definition": "Status indicating availability of an experimental drug or device outside any clinical trial protocol. (clinicaltrials.gov)", "preferredTerm": "Trial Expanded Access Status", "submissionValue": "Expanded Access Status", "synonyms": ["Expanded Access Status"]}, {"conceptId": "C98724", "definition": "Exploratory measures that will be used to evaluate the intervention(s) or, for observational studies, that are exploratory of the study.", "preferredTerm": "Exploratory Outcome Measure", "submissionValue": "Exploratory Outcome Measure", "synonyms": ["Exploratory Outcome Measure"]}, {"conceptId": "C123629", "definition": "An indication as to whether the study involves an FDA-regulated device.", "preferredTerm": "FDA-Regulated Device Study Indicator", "submissionValue": "FDA-Regulated Device Study Indicator", "synonyms": ["FDA-Regulated Device Study Indicator"]}, {"conceptId": "C123630", "definition": "An indication as to whether the study involves an FDA-regulated drug.", "preferredTerm": "FDA-Regulated Drug Study Indicator", "submissionValue": "FDA-Regulated Drug Study Indicator", "synonyms": ["FDA-Regulated Drug Study Indicator"]}, {"conceptId": "C98737", "definition": "Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study.", "preferredTerm": "Healthy Subject Indicator", "submissionValue": "Healthy Subject Indicator", "synonyms": ["Healthy Subject Indicator"]}, {"conceptId": "C98746", "definition": "The trial design developed to compare treatment groups.", "preferredTerm": "Intervention Model", "submissionValue": "Intervention Model", "synonyms": ["Intervention Model"]}, {"conceptId": "C98747", "definition": "The kind of product or procedure studied in a trial.", "preferredTerm": "Intervention Type", "submissionValue": "Intervention Type", "synonyms": ["Intervention Type"]}, {"conceptId": "C41161", "definition": "The investigational product under study.", "preferredTerm": "Protocol Agent", "submissionValue": "Investigational Therapy or Treatment", "synonyms": ["Investigational Therapy or Treatment"]}, {"conceptId": "C127794", "definition": "An indication as to whether the clinical study is being conducted at multiple sites within the European Union member state concerned by the application.", "preferredTerm": "Multiple Site European Union State Trial Indicator", "submissionValue": "Multiple Site EU State Trial Indicator", "synonyms": ["Multiple Site EU State Trial Indicator"]}, {"conceptId": "C126063", "definition": "The number of groups or cohorts that are part of the study.", "preferredTerm": "Number of Groups or Cohorts", "submissionValue": "Number of Groups/Cohorts", "synonyms": ["Number of Groups/Cohorts"]}, {"conceptId": "C127795", "definition": "The total number of trial sites within the European Union member state concerned by the application.", "preferredTerm": "Number of Trial Sites within European Union State", "submissionValue": "Number of Trial Sites EU State", "synonyms": ["Number of Trial Sites EU State"]}, {"conceptId": "C126066", "definition": "A description of the population from which the groups or cohorts will be selected within an observational study.", "preferredTerm": "Observational Study Population Description", "submissionValue": "Obs Study Population Description", "synonyms": ["Obs Study Population Description"]}, {"conceptId": "C126068", "definition": "A textual description of the sampling method used to assign study participants into groups or cohorts within an observational study.", "preferredTerm": "Observational Study Sampling Method Description", "submissionValue": "Obs Study Sampling Method Description", "synonyms": ["Obs Study Sampling Method Description"]}, {"conceptId": "C126064", "definition": "The trial design developed to compare biomedical and/or health outcomes in pre-defined and non-assigned groups of individuals.", "preferredTerm": "Observational Model", "submissionValue": "Observational Model", "synonyms": ["Observational Model"]}, {"conceptId": "C126067", "definition": "The sampling method used to assign study participants into groups or cohorts within an observational study.", "preferredTerm": "Observational Study Sampling Method", "submissionValue": "Observational Study Sampling Method", "synonyms": ["Observational Study Sampling Method"]}, {"conceptId": "C126065", "definition": "The temporal relationship between the observation period and time of subject enrollment. (ClinicalTrials.gov)", "preferredTerm": "Observational Time Perspective of Study", "submissionValue": "Observational Time Perspective", "synonyms": ["Observational Time Perspective"]}, {"conceptId": "C126069", "definition": "An indication as to whether the trial is part of a pediatric investigation plan (PIP).", "preferredTerm": "Pediatric Investigation Plan Indicator", "submissionValue": "Pediatric Investigation Plan Indicator", "synonyms": ["Pediatric Investigation Plan Indicator"]}, {"conceptId": "C123631", "definition": "An indication as to whether the study is a pediatric postmarket study.", "preferredTerm": "Pediatric Postmarket Study Indicator", "submissionValue": "Pediatric Postmarket Study Indicator", "synonyms": ["Pediatric Postmarket Study Indicator"]}, {"conceptId": "C123632", "definition": "An indication as to whether the study is a pediatric study.", "preferredTerm": "Pediatric Study Indicator", "submissionValue": "Pediatric Study Indicator", "synonyms": ["Pediatric Study Indicator"]}, {"conceptId": "C98768", "definition": "The pharmacological class of the investigational product.", "preferredTerm": "Pharmacological Class of Investigational Therapy", "submissionValue": "Pharmacologic Class", "synonyms": ["Pharmacologic Class"]}, {"conceptId": "C98770", "definition": "The country name of planned study facility which has received IRB approval.", "preferredTerm": "Planned Country of Investigational Site", "submissionValue": "Planned Country of Investigational Sites", "synonyms": ["Planned Country of Investigational Sites"]}, {"conceptId": "C49694", "definition": "The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Maximum Age of Subjects", "submissionValue": "Planned Maximum Age of Subjects", "synonyms": ["Planned Maximum Age of Subjects"]}, {"conceptId": "C49693", "definition": "The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Minimum Age of Subjects", "submissionValue": "Planned Minimum Age of Subjects", "synonyms": ["Planned Minimum Age of Subjects"]}, {"conceptId": "C98771", "definition": "The planned number of intervention groups.", "preferredTerm": "Planned Number of Arms", "submissionValue": "Planned Number of Arms", "synonyms": ["Planned Number of Arms"]}, {"conceptId": "C49692", "definition": "The planned number of subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Subject Number", "submissionValue": "Planned Number of Subjects", "synonyms": ["Anticipated Enrollment", "Planned Enrollment", "Planned Number of Subjects", "Target Enrollment"]}, {"conceptId": "C127796", "definition": "The approximate period of time over which the clinical trial is expected to occur.", "preferredTerm": "Planned Trial Duration", "submissionValue": "Planned Trial Duration", "synonyms": ["Planned Trial Duration"]}, {"conceptId": "C98772", "definition": "The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).", "preferredTerm": "Primary Outcome Measure", "submissionValue": "Primary Outcome Measure", "synonyms": ["Primary Outcome Measure"]}, {"conceptId": "C126062", "definition": "A word or small set of words designed to convey the focus of the protocol.", "preferredTerm": "Protocol Keyword", "submissionValue": "Protocol Keyword", "synonyms": ["Protocol Keyword"]}, {"conceptId": "C127797", "definition": "A globally unique identifier for a biomedical article, as assigned by PubMed.", "preferredTerm": "PubMed Identifier for Citation Used in Study", "submissionValue": "PubMed ID for Citation Used in Study", "synonyms": ["PubMed ID for Citation Used in Study"]}, {"conceptId": "C98775", "definition": "The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects.", "preferredTerm": "Randomization Quotient", "submissionValue": "Randomization Quotient", "synonyms": ["Randomization Quotient"]}, {"conceptId": "C126070", "definition": "An indication as to whether the condition under study is considered a rare disease.", "preferredTerm": "Rare Disease Indicator", "submissionValue": "Rare Disease Indicator", "synonyms": ["Rare Disease Indicator"]}, {"conceptId": "C98714", "definition": "Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries.", "preferredTerm": "Clinical Trial Registry Identifier", "submissionValue": "Registry Identifier", "synonyms": ["Registry Identifier"]}, {"conceptId": "C117961", "definition": "A standard from which a judgment concerning a disease relapse can be established.", "preferredTerm": "Relapse Criteria", "submissionValue": "Relapse Criteria", "synonyms": ["Relapse Criteria"]}, {"conceptId": "C127798", "definition": "An indication as to whether the registrant would like to receive an XML copy of their study as saved on EudraCT.", "preferredTerm": "Study Saved as XML Indicator", "submissionValue": "Request for XML Copy of Study Indicator", "synonyms": ["Request for XML Copy of Study Indicator"]}, {"conceptId": "C126071", "definition": "An alphabetic character that describes the incremental order of trial resubmissions.", "preferredTerm": "Resubmission Letter", "submissionValue": "Resubmission Letter", "synonyms": ["Resubmission Letter"]}, {"conceptId": "C126072", "definition": "A textual description of the specimen types that are retained as reserve samples.", "preferredTerm": "Retained Biospecimen Description", "submissionValue": "Retained Biospecimen Description", "synonyms": ["Retained Biospecimen Description"]}, {"conceptId": "C38114", "definition": "The course by which a substance was administered in order to reach the site of action in the body.", "preferredTerm": "Route of Administration", "submissionValue": "Route of Administration", "synonyms": ["Route of Administration"]}, {"conceptId": "C126073", "definition": "An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to a EudraVigiliance clinical trial module (EVCTM).", "preferredTerm": "SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator", "submissionValue": "SUSAR Reporting to EVCTM Indicator", "synonyms": ["SUSAR Reporting to EVCTM Indicator"]}, {"conceptId": "C126074", "definition": "An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to national competent authorities (NCA).", "preferredTerm": "SUSAR Reporting to National Competent Authority Indicator", "submissionValue": "SUSAR Reporting to NCA Indicator", "synonyms": ["SUSAR Reporting to NCA Indicator"]}, {"conceptId": "C98781", "definition": "Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).", "preferredTerm": "Secondary Outcome Measure", "submissionValue": "Secondary Outcome Measure", "synonyms": ["Secondary Outcome Measure"]}, {"conceptId": "C127799", "definition": "An indication as to whether the XML copy of the EudraCT application requires secure E-mail delivery.", "preferredTerm": "Requires Secure Email Delivery of XML Indicator", "submissionValue": "Secure Delivery XML Required Indicator", "synonyms": ["Secure Delivery XML Required Indicator"]}, {"conceptId": "C117962", "definition": "A standard from which a judgment concerning the severity of an event, disease or condition can be established.", "preferredTerm": "Severity Criteria", "submissionValue": "Severity Criteria", "synonyms": ["Severity Criteria"]}, {"conceptId": "C49696", "definition": "The specific sex, either male, female, or mixed of the subject group being studied. (NCI)", "preferredTerm": "Sex of Study Group", "submissionValue": "Sex of Participants", "synonyms": ["Sex of Participants"]}, {"conceptId": "C127800", "definition": "An indication as to whether the clinical study is being conducted at only one site within the European Union member state concerned by the application.", "preferredTerm": "Single Site European Union State Trial Indicator", "submissionValue": "Single Site EU State Trial Indicator", "synonyms": ["Single Site EU State Trial Indicator"]}, {"conceptId": "C98783", "definition": "The protocol specified minimum amount of time needed to meet the definition of stable disease.", "preferredTerm": "Stable Disease Minimum Duration", "submissionValue": "Stable Disease Minimum Duration", "synonyms": ["Stable Disease Minimum Duration"]}, {"conceptId": "C16153", "definition": "Selected pre-treatment factors by which patients are segregated to assure balance of these factors before randomization to the intervention arms of a clinical protocol.", "preferredTerm": "Stratification Factors", "submissionValue": "Stratification Factor", "synonyms": ["Stratification Factor"]}, {"conceptId": "C90462", "definition": "Final date on which data was collected for any subject (Date/Time of End of Participation, RFPENDTC) based on the protocol.", "preferredTerm": "Study End Date", "submissionValue": "Study End Date", "synonyms": ["Study End Date"]}, {"conceptId": "C69208", "definition": "The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included.", "preferredTerm": "Study Start Date", "submissionValue": "Study Start Date", "synonyms": ["Study Start Date"]}, {"conceptId": "C49698", "definition": "The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI)", "preferredTerm": "Study Stop Rule", "submissionValue": "Study Stop Rules", "synonyms": ["Study Stop Rules"]}, {"conceptId": "C15320", "definition": "Describes the role the study plays in determining the interventions a subject receives.", "preferredTerm": "Study Design", "submissionValue": "Study Type", "synonyms": ["Study Type"]}, {"conceptId": "C126075", "definition": "A textual description of the substudy.", "preferredTerm": "Substudy Details", "submissionValue": "Substudy Details", "synonyms": ["Substudy Details"]}, {"conceptId": "C126076", "definition": "An indication as to whether a study performed on a subgroup of subjects included in the original trial (substudy) is planned for the current study.", "preferredTerm": "Substudy Planned Indicator", "submissionValue": "Substudy Planned Indicator", "synonyms": ["Substudy Planned Indicator"]}, {"conceptId": "C126077", "definition": "The anticipated time period over which each study participant is to be followed. (ClinicalTrials.gov)", "preferredTerm": "Planned Follow-Up Duration", "submissionValue": "Target Follow-Up Duration", "synonyms": ["Target Follow-Up Duration"]}, {"conceptId": "C101302", "definition": "A knowledge field that focuses on research and development of specific treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual. (NCI)", "preferredTerm": "Therapeutic Area", "submissionValue": "Therapeutic Area", "synonyms": ["Therapeutic Area"]}, {"conceptId": "C49658", "definition": "The name of a code list that contains terms to define the type of blinding for the trial. (NCI)", "preferredTerm": "Trial Blinding Schema", "submissionValue": "Trial Blinding Schema", "synonyms": ["Trial Blinding Schema"]}, {"conceptId": "C112038", "definition": "The condition, disease or disorder that the clinical trial is intended to investigate or address.", "preferredTerm": "Trial Indication", "submissionValue": "Trial Indication", "synonyms": ["Trial Indication"]}, {"conceptId": "C49652", "definition": "The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI)", "preferredTerm": "Clinical Study by Intent", "submissionValue": "Trial Indication Type", "synonyms": ["Trial Indication Type"]}, {"conceptId": "C49697", "definition": "Planned length of observation for a single subject.", "preferredTerm": "Trial Length", "submissionValue": "Trial Length", "synonyms": ["Trial Length"]}, {"conceptId": "C48281", "definition": "Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI)", "preferredTerm": "Trial Phase", "submissionValue": "Trial Phase Classification", "synonyms": ["Trial Phase Classification"]}, {"conceptId": "C85826", "definition": "The principal purpose of the trial.", "preferredTerm": "Trial Primary Objective", "submissionValue": "Trial Primary Objective", "synonyms": ["Trial Primary Objective"]}, {"conceptId": "C85827", "definition": "The auxiliary purpose of the trial.", "preferredTerm": "Trial Secondary Objective", "submissionValue": "Trial Secondary Objective", "synonyms": ["Trial Secondary Objective"]}, {"conceptId": "C49802", "definition": "The name of a clinical trial. (NCI)", "preferredTerm": "Trial Title", "submissionValue": "Trial Title", "synonyms": ["Trial Title"]}, {"conceptId": "C49660", "definition": "The type of clinical trial performed e.g. efficacy, safety. (NCI)", "preferredTerm": "Trial Type", "submissionValue": "Trial Type", "synonyms": ["Trial Type"]}, {"conceptId": "C25196", "definition": "The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary)", "preferredTerm": "Randomization", "submissionValue": "Trial is Randomized", "synonyms": ["Trial is Randomized"]}, {"conceptId": "C127801", "definition": "The uniform resource locator (URL) related to a particular study.", "preferredTerm": "Study Protocol Uniform Resource Locator", "submissionValue": "URL Related to Study", "synonyms": ["URL Related to Study"]}, {"conceptId": "C127802", "definition": "A textual description of the uniform resource locator (URL) related to a particular study.", "preferredTerm": "Study Protocol Uniform Resource Locator Description", "submissionValue": "URL Related to Study Description", "synonyms": ["URL Related to Study Description"]}]}